Bluelight Partners

Health professionals make considerable use of mobile phones during their working day, as do their patients. As the popularity of running software applications on mobile devices continues to increase, we anticipate that the use of apps to aid medical diagnosis and treatment will continue to gain in popularity with a corresponding increase in risk to [...]

How safe is that app? Should pharma apps be registered as medical devices? Written by Sam Walmsley and Paul Dixey at Bluelight Partners What impact does the first app to be registered as a medical device with the MHRA have upon pharmaceutical companies and the apps they produce? EMBARGO 8am 10th January 2012 10 January 2012, London – [...]

It is now nearly one year since the PMCPA released Digital Guidelines to go alongside the ABPI Code of Practice. Despite much commentary and repeated requests by many in the pharmaceutical industry it is only the PMCPA in the UK and LIF, the trade association for the research-based pharmaceutical industry in Sweden, that have issued such guidance. It is now over 2 years since the FDA held hearings but have only in December 2011 issued draft guidelines limited to how to respond to unsolicited requests for information about off-label use.

Health professionals make considerable use of mobile phones during their working day, as do their patients. As the popularity of running software applications on mobile devices continues to increase, we anticipate that the use of apps to aid medical diagnosis and treatment will continue to gain in popularity with a corresponding increase in risk to [...]

How safe is that app? Should pharma apps be registered as medical devices? Written by Sam Walmsley and Paul Dixey at Bluelight Partners What impact does the first app to be registered as a medical device with the MHRA have upon pharmaceutical companies and the apps they produce? EMBARGO 8am 10th January 2012 10 January 2012, London – [...]

The ABPI Code of Practice for the Pharmaceutical Industry 2012 is available to download from the PMCPA website. There are no changes from the 2011 Code related to online activities

It is now nearly one year since the PMCPA released Digital Guidelines to go alongside the ABPI Code of Practice. Despite much commentary and repeated requests by many in the pharmaceutical industry it is only the PMCPA in the UK and LIF, the trade association for the research-based pharmaceutical industry in Sweden, that have issued such guidance. It is now over 2 years since the FDA held hearings but have only in December 2011 issued draft guidelines limited to how to respond to unsolicited requests for information about off-label use.

Infographic by- Shanghai Web Designers Did you know in 60 seconds: Search engine Google serves more that 694,445 queries 6,600+ pictures are uploaded on Flickr   600 videos are uploaded on YouTube videos, amounting to 25+ hours of content 695,000 status updates, 79,364 wall posts and 510,040 comments are published on Social Networking site Facebook [...]

“Bringing Digital into Strategy and Operations for integrated multi-channel marketing …..or….I wouldn’t start from here !” Slides from Informa Webinar. June 2011

Health professionals make considerable use of mobile phones during their working day, as do their patients. As the popularity of running software applications on mobile devices continues to increase, we anticipate that the use of apps to aid medical diagnosis and treatment will continue to gain in popularity with a corresponding increase in risk to [...]

How safe is that app? Should pharma apps be registered as medical devices? Written by Sam Walmsley and Paul Dixey at Bluelight Partners What impact does the first app to be registered as a medical device with the MHRA have upon pharmaceutical companies and the apps they produce? EMBARGO 8am 10th January 2012 10 January 2012, London – [...]

It is now nearly one year since the PMCPA released Digital Guidelines to go alongside the ABPI Code of Practice. Despite much commentary and repeated requests by many in the pharmaceutical industry it is only the PMCPA in the UK and LIF, the trade association for the research-based pharmaceutical industry in Sweden, that have issued such guidance. It is now over 2 years since the FDA held hearings but have only in December 2011 issued draft guidelines limited to how to respond to unsolicited requests for information about off-label use.

Health professionals make considerable use of mobile phones during their working day, as do their patients. As the popularity of running software applications on mobile devices continues to increase, we anticipate that the use of apps to aid medical diagnosis and treatment will continue to gain in popularity with a corresponding increase in risk to [...]

“Bringing Digital into Strategy and Operations for integrated multi-channel marketing …..or….I wouldn’t start from here !” Slides from Informa Webinar. June 2011

Paul Dixey took part in a BrightTALK® webcast discussing both the regulatory challenges and the approaches that Pharma can take when seeking to participate in social media. Click on Full Article to view the webcast recording and the slide set.